Previous studies have demonstrated that B2036, a hGH antagonist, decreased oncogenicity of endometrial carcinoma cells [4] and decreased proliferation of primary human mammary carcinoma cells in vitro [58]. Here, GH1 is linked to endometrial carcinoma.